Investigational drug · Phase 3
AT-1501
Also called: Tegoprubart
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Kidney Transplant Rejection, Prevention of Rejection in Kidney Transplant.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
3 still active
All registered trials
9
Any phase or sponsor naming "AT-1501"
First trial start
2022
Feb 18, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AT-1501", any sponsor or status.
Conditions studied
As listed on its trial records.
- Kidney Transplant Rejection
- Prevention of Rejection in Kidney Transplant
Approved drugs for the same conditions: Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "AT-1501" as an intervention, largest first.
- Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney TransplantationPivotal-lookingNot yet recruiting
Eledon PharmaceuticalsIndustry
NCT07835581 · 620 participants (planned) · Start Oct 2026 · Primary completion Mar 2029
Drug: Tegoprubart; Tacrolimus · For: Kidney Transplant Rejection
- Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant RecipientsEnrolling by invitation
Eledon PharmaceuticalsIndustry
NCT06126380 · 132 participants (planned) · Start Oct 25, 2023 · Primary completion Dec 2029
Drug: AT-1501; Tacrolimus · For: Kidney Transplant Rejection
Sites: Los Angeles, California; Orange, California; Sacramento, California · 43 sites in all
- Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney TransplantationPivotal-lookingCompleted
Eledon PharmaceuticalsIndustry
NCT05983770 · 127 participants · Start Aug 30, 2023 · Primary completion Sep 11, 2025
Drug: AT-1501; Tacrolimus · For: Kidney Transplant Rejection
Sites: Los Angeles, California; Orange, California; Sacramento, California · 43 sites in all
- Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)Active, not recruiting
University of ChicagoAcademic, hospital or other
NCT06305286 · 70 participants (planned) · Start Mar 4, 2024 · Primary completion Mar 2029
Drug: Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy · For: Type 1 Diabetes Mellitus
Sites: Chicago, Illinois
Anelixis Therapeutics, LLCIndustry
NCT04322149 · 54 participants · Start Oct 16, 2020 · Primary completion Mar 24, 2022
Drug: AT-1501 · For: Amyotrophic Lateral Sclerosis
Sites: Phoenix, Arizona; Orange, California; San Francisco, California · 13 sites in all
- Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney TransplantRecruiting
Eledon PharmaceuticalsIndustry
NCT05027906 · 48 participants (planned) · Start Feb 18, 2022 · Primary completion Jan 2027
Drug: AT-1501 · For: Prevention of Rejection in Kidney Transplant
Sites: Cincinnati, Ohio; Camperdown, Australia; Adelaide, Australia · 9 sites in all
Eledon PharmaceuticalsIndustry
NCT05125068 · 24 participants · Start Mar 21, 2022 · Primary completion Jul 31, 2023
Drug: AT-1501 · For: IgA Nephropathy; IgAN
Sites: Liverpool, Australia; Clayton, Australia; St Albans, Australia · 26 sites in all
- Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell TransplantationWithdrawn
Anelixis Therapeutics, LLCIndustry
NCT04711226 · 0 participants · Start Feb 19, 2021 · Primary completion Jun 2024
Drug: AT-1501 · For: Type 1 Diabetes Mellitus
Sites: Edmonton, Canada
Eledon PharmaceuticalsIndustry
NCT05480657 · 0 participants · Start Sep 30, 2022 · Primary completion Aug 2024
Drug: AT-1501 IV Infusion; Isolated cadaveric islet cells · For: Brittle Type 1 Diabetes Mellitus
Sites: Chicago, Illinois
Newest research
PubMed records naming it or its code names, newest first.
- Gene-edited hypoimmune islets as a cure for type 1 diabetes: a review of the immunological challenges.
Hassanein A, Cyprian F, Akhtar S · Expert Opin Biol Ther 2026
- Costimulation blockade: the next generation.
Yakubu I, Moinuddin I, Brown A, et al. · Curr Opin Organ Transplant 2025
- Transplantation of a genetically modified porcine heart into a live human.
Griffith BP, Grazioli A, Singh AK, et al. · Nat Med 2025
- New Developments and Therapeutic Drug Monitoring Options in Costimulatory Blockade in Solid Organ Transplantation: A Systematic Critical Review.
de Graav GN, Udomkarnjananun S, Baan CC, et al. · Ther Drug Monit 2025
- Safety and tolerability of tegoprubart in patients with amyotrophic lateral sclerosis: A Phase 2A clinical trial.
Perrin S, Ladha S, Maragakis N, et al. · PLoS Med 2024
- The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates.
Anwar IJ, Berman DM, DeLaura I, et al. · Sci Transl Med 2023
Also in development for Kidney Transplant Rejection
- FrexalimabSAR441344Phase 39 trials
Sanofi · Multiple Sclerosis, Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.